Cao Y R, Zhang J, Liu H, Zhang W
Xi'an Medical University, Xi'an, 710068, China.
Department of Otorhinolaryngology Head and Neck Surgery, Shaanxi Provincial People's Hospital.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Oct 5;32(19):1483-1486. doi: 10.13201/j.issn.1001-1781.2018.19.010.
To investigate the clinical value of the seven-item Eustachian Tube Dysfunction Questionnaire(ETDQ-7) in evaluating Eustachian tube dysfunction before and after treatment. A retrospective analysis of 50 patients with Eustachian tube dysfunction diagnosed. All the patients were given chymotrypsin 4 000 IU and dexamethasone injection 5 mg by blowing through the Eustachian tube under nasal endoscopic guidance once daily for 3-6 consecutive days. At the same time, azelastine hydrochloride nasal spray and budesonide nasal spray were applied, 2 sprays each time, 2 times a day; oral Olongma drops, 3 ml each time, 3 times a day. ETDQ-7 was completed before and after treatment, and the results of ear endoscopy, pure tone audiometry, acoustic impedance test, and Eustachian tube function test were analyzed comprehensively. The ETDQ-7 score(15.6±7.1) after treatment was significantly higher than that before treatment(23.1±6.5) points (<0.05), and the difference was statistically significant. After treatment, all patients felt that aural fullness, tinnitus or discomfort, hearing loss and other symptoms were relieved. The tympanic membrane was observed to be better than before treatment. The tympanic effusion and tympanic membrane invagination were improved, which was in line with the change of ETDQ-7 score. ETDQ-7 has a good clinical value in the evaluation of Eustachian tube dysfunction before and after treatment. It is a reproducible and effective method for evaluating Eustachian tube dysfunction(ETD).
探讨七项咽鼓管功能障碍问卷（ETDQ - 7）在评估治疗前后咽鼓管功能障碍中的临床价值。对50例诊断为咽鼓管功能障碍的患者进行回顾性分析。所有患者在鼻内镜引导下经咽鼓管吹入糜蛋白酶4000 IU和地塞米松注射液5 mg，每日1次，连续3 - 6天。同时，应用盐酸氮卓斯汀鼻喷雾剂和布地奈德鼻喷雾剂，每次2喷，每日2次；口服欧龙马滴剂，每次3 ml，每日3次。治疗前后完成ETDQ - 7问卷，并综合分析耳内镜、纯音听力测试、声阻抗测试及咽鼓管功能测试结果。治疗后ETDQ - 7评分（15.6±7.1）分显著高于治疗前（23.1±6.5）分（P<0.05），差异有统计学意义。治疗后所有患者自觉耳闷、耳鸣或不适、听力下降等症状均有缓解。观察鼓膜情况较治疗前好转。鼓室积液及鼓膜内陷改善，与ETDQ - 7评分变化相符。ETDQ - 7在评估治疗前后咽鼓管功能障碍方面具有良好的临床价值。它是一种可重复且有效的评估咽鼓管功能障碍（ETD）的方法。
